IMUNON, INC.

IMNN

CIK 0000749647 · Quarterly mode · latest period FY2022 (Q4) (ending 2022-12-31) · sourced from SEC EDGAR

At a glance · FY2022 (Q4)

Revenue
$125K
↑+0.0% +$0vs FY2021 (Q4)
Gross Profit
$125K
↑+0.0% +$0vs FY2021 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0ROIC -204.7% (10% = solid, 20%+ = moat)
  • Liquidity
    91Current Ratio 2.32 (above 1.5 = solid)
  • Leverage
    90D/E 0.20 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.01x (1.0+ = capital-efficient)
  • Growth
    17Revenue YoY +0.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$281K
investment in PP&E
Stock-based comp (TTM)
$339K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$12M
everything owned
Total liabilities
$5M
everything owed
Stockholders' equity
$7M
shareholder claim
Net debt
$-3M
Net cash position ($3M)

Recent performance · 63 quarters

Revenue↑+0.0% +$0
$125K
Net Income↑+29.2% +$1M
$-3M
Free Cash Flow↑+75.9% +$11K
$-4K
Operating Margin↓-890.4pts
-4939.7%

Drill down